◼ Archived
Business
Artiva to discontinue cell therapy after two patient deaths, cut workforce by 94%
Artiva Biotherapeutics is discontinuing its autoimmune cell therapy and cutting 94 percent of its staff following patient deaths.
1 trends tracked about this subject — the full history, oldest to newest below.
Artiva Biotherapeutics is discontinuing its autoimmune cell therapy and cutting 94 percent of its staff following patient deaths.